FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.
What happened
FDA inspected the drug manufacturing facility from October 11 to 17, 2023, and reviewed the company’s November 3, 2023, response to the inspection observations (Form FDA 483). FDA found that the company released OTC drugs without adequate potency and microbiological testing and did not identity-test incoming raw materials. FDA also found the quality unit failed to ensure written production controls, an ongoing stability program, and appropriate equipment cleaning.
What FDA found
The company did not test each finished drug batch for identity and strength before release; it used only a density meter for strength testing and did not adequately test potency or microbiology for hand sanitizer and isopropyl alcohol.
21 CFR 211.165(a)The company did not perform at least one identity test on each incoming raw material lot used to make its OTC drugs.
21 CFR 211.84(d)(1)The quality unit failed to ensure adequate written procedures for production and process controls.
21 CFR 211.100(a)The quality unit failed to ensure an adequate ongoing stability program.
21 CFR 211.166(a)The quality unit failed to ensure manufacturing equipment for OTC drugs was cleaned at appropriate intervals.
21 CFR 211.67(a)The quality unit failed to exercise its responsibility to ensure drug products met CGMP and established specifications for identity, strength, quality, and purity.
21 CFR 211.22
What FDA wants
FDA tells the company to respond in writing within 15 working days with corrective actions, including full chemical and microbiological testing and an independent laboratory assessment. FDA also asks for DEG and EG test results from high-risk component retains or implicated finished product within 30 calendar days.
Who should pay attention
- brands or distributors selling OTC hand sanitizer, alcohol, or peroxide from this manufacturer
- suppliers and buyers of glycerin, ethanol, or isopropyl alcohol
- quality teams managing raw material identity and DEG/EG testing
This is a summary. Read the original letter on fda.gov.